These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29443503)

  • 21. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
    LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
    MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing.
    Lakayan D; Haselberg R; Gahoual R; Somsen GW; Kool J
    Anal Bioanal Chem; 2018 Dec; 410(30):7837-7848. PubMed ID: 30328504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells.
    Wichmann H; Güttler A; Bache M; Taubert H; Rot S; Kessler J; Eckert AW; Kappler M; Vordermark D
    Strahlenther Onkol; 2015 Feb; 191(2):180-91. PubMed ID: 25159136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.
    Oliveras-Ferraros C; Massaguer Vall-Llovera A; Vazquez-Martin A; Salip DC; Queralt B; Cufí S; Martin-Castillo B; Bosch-Barrera J; Brunet J; De Llorens R; Menendez JA
    Oncol Rep; 2012 Jun; 27(6):1887-92. PubMed ID: 22427198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Progression of antibody therapy in the cancer therapy: anti-CCR4 antibody and others].
    Ito A; Ueda R
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(2):118-28. PubMed ID: 22576569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioluminescent sensor proteins for point-of-care therapeutic drug monitoring.
    Griss R; Schena A; Reymond L; Patiny L; Werner D; Tinberg CE; Baker D; Johnsson K
    Nat Chem Biol; 2014 Jul; 10(7):598-603. PubMed ID: 24907901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Affinity Maturation of a Cyclic Peptide Handle for Therapeutic Antibodies Using Deep Mutational Scanning.
    van Rosmalen M; Janssen BM; Hendrikse NM; van der Linden AJ; Pieters PA; Wanders D; de Greef TF; Merkx M
    J Biol Chem; 2017 Jan; 292(4):1477-1489. PubMed ID: 27974464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma levels of trastuzumab in gastric cancer: Case report.
    González-García J; Alonso-Alvarez B; Nazco-Casariego GJ; Batista-López N; Guttiérrez-Nicolás F
    J Oncol Pharm Pract; 2017 Dec; 23(8):635-637. PubMed ID: 27664112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
    Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
    Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy.
    Shin TH; Sung ES; Kim YJ; Kim KS; Kim SH; Kim SK; Lee YD; Kim YS
    Mol Cancer Ther; 2014 Mar; 13(3):651-61. PubMed ID: 24435448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors.
    Lee CM; Tannock IF
    BMC Cancer; 2010 Jun; 10():255. PubMed ID: 20525277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
    Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
    Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid and simultaneous quantification of a mixture of biopharmaceuticals by a liquid chromatography/quadrupole time-of-flight mass spectrometric method in rat plasma following cassette-dosing.
    Park MH; Byeon JJ; Shin SH; Kim N; Park Y; Ill Lee B; Choi J; Shin YG
    Rapid Commun Mass Spectrom; 2018 Jun; 32(11):889-896. PubMed ID: 29578307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting.
    Singer J; Weichselbaumer M; Stockner T; Mechtcheriakova D; Sobanov Y; Bajna E; Wrba F; Horvat R; Thalhammer JG; Willmann M; Jensen-Jarolim E
    Mol Immunol; 2012 Apr; 50(4):200-9. PubMed ID: 22424313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.
    Pedersen MW; Jacobsen HJ; Koefoed K; Dahlman A; Kjær I; Poulsen TT; Meijer PJ; Nielsen LS; Horak ID; Lantto J; Kragh M
    Mol Cancer Ther; 2015 Mar; 14(3):669-80. PubMed ID: 25612619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells.
    Meira DD; de Almeida VH; Mororó JS; Nóbrega I; Bardella L; Silva RL; Albano RM; Ferreira CG
    Br J Cancer; 2009 Sep; 101(5):782-91. PubMed ID: 19654571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.